



DPW

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/817,570	
	Filing Date	April 1, 2004	
	First Named Inventor	Charles David Claude	
	Group Art Unit	1615	
	Examiner Name	Unassigned	
Total Number of Pages in This Submission (excluding references)	6	Attorney Docket Number	5063.00384

ENCLOSURES (check all that apply)		
<input checked="" type="checkbox"/> Deposit Account 07-1850 Authorization	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Postage Paid Return Postcard	<input type="checkbox"/> Drawing(s) In/Formal ____ Sheets with Submission of Drawings Transmittal	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Amendment Transmittal Letter (in duplicate)	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Petition for Extension of Time (____ months) (in duplicate)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input checked="" type="checkbox"/> Information Disclosure Statement (in duplicate) with Form PTO-1449 citing 64 References	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Express Mail Label No.	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) ____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Squire, Sanders & Dempsey L.L.P. Cameron Kerrigan / Reg. No. 44,826
Signature	
Date	November 1, 2004

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: November 19, 2004			
Typed or printed name	Vera Breder		
Signature		Date	November 19, 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Examiner: Unassigned

Charles David Claude

Serial No. 10/817,570

Art Unit: 1615

Filed: April 1, 2004

Title: CONTROLLED MORPHOLOGIES IN POLYMER DRUG FOR
RELEASE OF DRUGS FROM POLYMER FILMS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§1.97-1.98**

Dear Examiner:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and pursuant to 37 C.F.R. §§1.97-1.98, Applicant hereby notifies the U.S. Patent and Trademark Office of the references listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/822,952, filed on March 30, 2001, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant reserves the right to dispute the listed documents as prior art during examination. Furthermore, Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application. The submission of this Information Disclosure Statement is not to be construed as a representation that a search has been made or that no other material information may exist.


The Examiner is requested to initial the enclosed Form PTO-1449 and return a copy thereof to the undersigned.

The present Information Disclosure Statement is being filed before receiving the first Office Action. Therefore, no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required. However, the Commissioner is authorized to charge any deficiencies or other amounts due to Deposit Account No. 07-1850.

Date: November 19, 2004

SQUIRE, SANDERS & DEMPSEY L.L.P.
One Maritime Plaza, Suite 300
San Francisco, CA 94111
Telephone (415) 954-0200
Facsimile (415) 393-9887

Respectfully submitted,


Cameron Kerrigan
Attorney for Applicant
Reg. No. 44,826

FORM PTO-1449 (Modified)
 Approved for use through 10/31/2002

US DEPARTMENT OF COMMERCE
 US Patent and Trademark Office

Docket No.
 50623.00384

Application No.
 10/817,570

INFORMATION DISCLOSURE CITATION in an Application

(Use several sheets if necessary)

Applicant
 Charles David Claude

Filing Date
 April 1, 2004

Group Art Unit
 1615

U.S. PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Patent	Name	Class	Subclass	Filing Date if Appropriate
	A1	2,072,303	3/2/37	Herrmann et al.	128	335.5	10/14/33
	A2	4,882,168	11/21/89	Casey et al.	424	468	9/5/86
	A3	4,977,901	12/18/90	Ofstead	128	772	4/6/90
	A4	5,292,516	3/8/94	Viegas et al.	424	423	11/8/91
	A5	5,298,260	3/29/94	Viegas et al.	424	486	6/9/92
	A6	5,300,295	4/5/94	Viegas et al.	424	427	9/13/91
	A7	5,306,501	4/26/94	Viegas et al.	424	423	11/8/91
	A8	5,328,471	7/12/94	Slepian	604	101	8/4/93
	A9	5,330,768	7/19/94	Park et al.	424	501	7/5/91
	A10	5,462,990	10/31/95	Hubbell et al.	525	54.1	10/5/93
	A11	5,464,650	11/7/95	Berg et al.	427	2.30	4/26/93
	A12	5,578,073	11/26/96	Haimovich et al.	623	1	9/16/94
	A13	5,605,696	2/25/97	Eury et al.	424	423	3/30/95
	A14	5,628,730	5/13/97	Shapland et al.	604	21	7/18/94
	A15	5,658,995	8/19/97	Kohn et al.	525	432	11/27/95
	A16	5,667,767	9/16/97	Greff et al.	424	9.411	7/27/95
	A17	5,670,558	9/23/97	Onishi et al.	523	112	7/6/95
	A18	5,700,286	12/23/97	Tartaglia et al.	623	1	8/22/96
	A19	5,716,981	2/10/98	Hunter et al.	514	449	6/7/95
	A20	5,746,998	5/5/98	Torchilin et al.	424	9.4	8/8/96
	A21	5,800,392	9/1/98	Racchini	604	96	5/8/96
	A22	5,824,049	10/20/98	Ragheb et al.	623	1	10/31/96
	A23	5,830,178	11/3/98	Jones et al.	604	49	10/11/96
	A24	5,837,313	11/17/98	Ding et al.	427	2.21	6/13/96
	A25	5,851,508	12/22/98	Greff et al.	424	9.411	2/14/97
	A26	5,865,814	2/2/99	Tuch	604	265	8/6/97
	A27	5,873,904	2/23/99	Ragheb et al.	623	1	2/24/97

	A28	5,925,720	7/20/99	Kataoka et al.	525	523	12/18/97
	A29	5,955,509	9/21/99	Webber et al.	514	772.7	4/23/97
	A30	5,971,954	10/26/99	Conway et al.	604	96	1/29/97
	A31	5,980,928	11/9/99	Terry	424	427	7/29/97
	A32	5,980,972	11/9/99	Ding	427	2.24	9/22/97
	A33	6,001,382	12/99	Levy	424	405	
	A34	6,010,530	1/4/00	Goicoechea	623	1	2/18/98
	A35	6,015,541	1/18/00	Greff et al.	424	1.25	11/3/97
	A36	6,060,518	5/9/00	Kabanov et al.	514	781	8/16/96
	A37	6,096,070	8/1/00	Ragheb et al.	623	1	5/16/96
	A38	6,153,252	11/28/00	Hossainy et al.	427	2.3	4/19/99
	A39	6,165,212	12/26/00	Dereume et al.	623	1.13	6/28/99

U.S. PATENT APPLICATION PUBLICATION DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Name	Class	Subclass	Filing Date if Appropriate
------------------	----------	-----------------	---------------------	------	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

Examiner Initial	Ref. No.	Document Number	Date of Publication	Country	Class	Subclass	Translation	
							Yes	No
	B1	EP 0 665 023	8/2/95	European				
	B2	WO 97/45105	12/4/97	PCT				
	B3	WO 99/63981	12/16/99	PCT				
	B4	WO 91/12846	9/91	PCT				
	B5	EP 0 970 711	1/12/00	European				
	B6	WO 00/12147	3/9/00	PCT				
	B7	WO 00/64506	11/2/00	PCT				
	B8	WO 01/01890	1/11/01	PCT				
	B9	WO 01/17577	3/15/01	PCT				
	B10	WO 01/45763	6/28/01	PCT				
	B11	WO 01/74414	10/11/01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Aoyagi et al., <i>Preparation of cross-linked aliphatic polyester and application to thermo-responsive material</i> , Journal of Controlled Release 32:87-96 (1994).
	C2	Barath et al., <i>Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury</i> , JACC 13(2): 252A (Abstract) (Feb. 1989).
	C3	Chung et al., <i>Inner core segment design for drug delivery control of thermo-responsive polymeric micelles</i> , Journal of Controlled Release 65:93-103 (2000).

C4	Inoue et al., <i>An AB block copolymer of oligo(methyl methacrylate) and poly(acrylic acid) for micellar delivery of hydrophobic drugs</i> , Journal of Controlled Release 51:221-229 (1998).		
C5	Kataoka et al., <i>Block copolymer micelles as vehicles for drug delivery</i> , Journal of Controlled Release 24:119-132 (1993).		
C6	Liu et al., <i>Drug release characteristics of unimolecular polymeric micelles</i> , Journal of Controlled Release 68:167-174 (2000).		
C7	Marconi et al., <i>Covalent bonding of heparin to a vinyl copolymer for biomedical applications</i> , Biomaterials 18(12):885-890 (1997).		
C8	Matsumaru et al., <i>Embolic Materials For Endovascular Treatment of Cerebral Lesions</i> , J. Biomater. Sci. Polymer Edn 8(7):555-569 (1997).		
C9	Miyazaki et al., <i>Antitumor Effect of Implanted Ethylene-Vinyl Alcohol Copolymer Matrices Containing Anticancer Agents on Ehrlich Ascites Carcinoma and P388 Leukemia in Mice</i> , Chem. Pharm. Bull. 33(6) 2490-2498 (1985).		
C10	Miyazawa et al., <i>Effects of Pemirolast and Tranilast on Intimal Thickening After Arterial Injury in the Rat</i> , J. Cardiovasc. Pharmacol., pp. 157-162 (1997).		
C11	Ohsawa et al., <i>Preventive Effects of an Antiallergic Drug, Pemirolast Potassium, on Restenosis After Percutaneous Transluminal Coronary Angioplasty</i> , American Heart Journal 136(6):1081-1087 (Dec. 1998).		
C12	Pechar et al., <i>Poly(ethylene glycol) Multiblock Copolymer as a Carrier of Anti-Cancer Drug Doxorubicin</i> , Bioconjugate Chemistry 11(2):131-139 (Mar./Apr. 2000).		
C13	Shigeno, <i>Prevention of Cerebrovascular Spasm By Bosentan, Novel Endothelin Receptor</i> , Chemical Abstract 125:212307 (1996).		
C14	Yokoyama et al., <i>Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor</i> , Journal of Controlled Release 50:79-92 (1998).		
<table border="1" style="width: 100%;"> <tr> <td style="width: 50%;">EXAMINER</td> <td style="width: 50%;">DATE CONSIDERED</td> </tr> </table>		EXAMINER	DATE CONSIDERED
EXAMINER	DATE CONSIDERED		
<p>EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered.</p> <p>Include copy of this form with next communication to applicant.</p>			